Shots:

• AbbVie exercised its exclusive right to acquire TeneoOne and its TNB-383B based on an interim analysis of an ongoing P-I study that demonstrated ORR (79%)- VGPR (63%)- CR (29%) at doses ≥40 mg in the dose-escalation cohorts with a median follow-up time of 6.1 mos.- m-DOR has not been reached
• In Feb’2019- AbbVie and TeneoOne collaborated to develop & commercialize TNB-383B that targets BCMA and CD3 & designed to direct the body immune system to kill BCMA-expressing tumor cells
• Abbvie will use Teneobio’s anti-CD3 platform to assess its clinical validation. At RP2D of TNB-383B (60 mg- q3w- IV) for MM showed a 67% CRS rate in all grades

  | Ref: PR Newswire | Image: abbvie